Literature DB >> 2487155

Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes.

W L Flejter1, F P Li, K H Antman, J R Testa.   

Abstract

Cytogenetic analysis was performed on short-term cultures of primary tumor tissue obtained from five patients with pleural malignant mesothelioma. Clonal karyotypic abnormalities were detected in four patients, none of whom had received cytotoxic therapy prior to karyotypic evaluation. Recurring chromosomal changes included partial deletions of 1p and 3p, and monosomy of 18, 19, and 22. We also reviewed data on 24 previously reported pretreatment patients and determined that alterations of chromosomes 1, 3, and 22 are frequently associated with malignant mesothelioma. Partial loss of chromosome 1 due to deletions or other rearrangements most frequently involve bands 1p11-pter with the shortest region of overlap (SRO) occurring at 1p21-p22 in our patients. Deletions and other structural changes of chromosome 3 usually involve the region 3p14-p25. The SRO of 3p deletions appeared to be at band 3p21. Monosomy 22 represents the most consistent specific whole chromosome loss seen in malignant mesothelioma, being observed in 11 of 28 cases summarized. In addition, structural changes of 22q have been observed in three patients, and a breakpoint at 22q11 was reported in each case. Taken collectively, these data suggest that a cascade of events involving alterations of genes on more than one specific chromosome may play a critical role in the development of malignant mesothelioma. The pattern of recurring chromosomal loss, particularly of 1p, 3p, and 22q, indicates that these regions should be targeted for future molecular investigations into the possible involvement of suppressor genes in this malignancy.

Entities:  

Mesh:

Year:  1989        PMID: 2487155     DOI: 10.1002/gcc.2870010207

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  16 in total

1.  Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.

Authors:  Yoshiaki Kinoshita; Makoto Hamasaki; Masayo Yoshimura; Shinji Matsumoto; Akinori Iwasaki; Kazuki Nabeshima
Journal:  Mod Pathol       Date:  2019-06-23       Impact factor: 7.842

2.  Fluorescence in situ hybridization evaluation of chromosome deletion patterns in prostate cancer.

Authors:  S F Huang; S Xiao; A A Renshaw; K R Loughlin; T J Hudson; J A Fletcher
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

3.  Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines.

Authors:  Geula Klorin; Ester Rozenblum; Oleg Glebov; Robert L Walker; Yoonsoo Park; Paul S Meltzer; Ilan R Kirsch; Frederic J Kaye; Anna V Roschke
Journal:  Cancer Genet       Date:  2013-07-05

Review 4.  The genetic susceptibility in the development of malignant pleural mesothelioma.

Authors:  Ombretta Melaiu; Federica Gemignani; Stefano Landi
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 5.  Oncogenes and tumor-suppressor genes in mesothelioma--a synopsis.

Authors:  J F Lechner; J Tesfaigzi; B I Gerwin
Journal:  Environ Health Perspect       Date:  1997-09       Impact factor: 9.031

Review 6.  Ependymoma.

Authors:  Charles Teo; Peter Nakaji; Patricia Symons; Vivienne Tobias; Richard Cohn; Robert Smee
Journal:  Childs Nerv Syst       Date:  2003-05-22       Impact factor: 1.475

7.  Inflammation-Related IL1β/IL1R Signaling Promotes the Development of Asbestos-Induced Malignant Mesothelioma.

Authors:  Yuwaraj Kadariya; Craig W Menges; Jacqueline Talarchek; Kathy Q Cai; Andres J Klein-Szanto; Ralph A Pietrofesa; Melpo Christofidou-Solomidou; Mitchell Cheung; Brooke T Mossman; Arti Shukla; Joseph R Testa
Journal:  Cancer Prev Res (Phila)       Date:  2016-03-02

8.  Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma.

Authors:  Mayura Meerang; Karima Bérard; Martina Friess; Byron K Y Bitanihirwe; Alex Soltermann; Bart Vrugt; Emanuela Felley-Bosco; Raphael Bueno; William G Richards; Burkhardt Seifert; Rolf Stahel; Walter Weder; Isabelle Opitz
Journal:  Mol Oncol       Date:  2016-06-25       Impact factor: 6.603

9.  Factors that impact susceptibility to fiber-induced health effects.

Authors:  Jennifer E Below; Nancy J Cox; Naomi K Fukagawa; Ari Hirvonen; Joseph R Testa
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

10.  Germline BAP1 mutations predispose to malignant mesothelioma.

Authors:  Joseph R Testa; Mitchell Cheung; Jianming Pei; Jennifer E Below; Yinfei Tan; Eleonora Sementino; Nancy J Cox; A Umran Dogan; Harvey I Pass; Sandra Trusa; Mary Hesdorffer; Masaki Nasu; Amy Powers; Zeyana Rivera; Sabahattin Comertpay; Mika Tanji; Giovanni Gaudino; Haining Yang; Michele Carbone
Journal:  Nat Genet       Date:  2011-08-28       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.